Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00241436 · ClinicalTrials.gov registry record · Phase 2
Open Label Arimidex in Gynecomastia
A Phase 2 study of Gynecomastia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00241436 is a Phase 2 study of Gynecomastia that has completed, run by AstraZeneca. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00241436, a Phase 2 study of Gynecomastia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety, effectiveness, pharmacokinetics and pharmacodynamics of anastrozole (ARIMIDEX™) in the treatment of boys with gynecomastia.
Conditions Studied
Interventions
- DRUG Anastrozole (ARIMIDEX™)
Study Locations (1)
Florida
- Research Site - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00241436
The ClinicalTrials.gov registry entry for NCT00241436 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gynecomastia appearing as the primary indexed condition, and to 1 intervention - of which Anastrozole (ARIMIDEX™) is the first listed.
NCT00241436 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00241436 about?
NCT00241436 is a clinical study titled "Open Label Arimidex in Gynecomastia". The purpose of this study is to evaluate the safety, effectiveness, pharmacokinetics and pharmacodynamics of anastrozole (ARIMIDEX™) in the treatment of boys with gynecomastia.
What is the current status of trial NCT00241436?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2005-06. Estimated completion is 2006-11.
What conditions does trial NCT00241436 study?
This clinical trial studies the following conditions: Gynecomastia.
What interventions are being tested in trial NCT00241436?
The interventions under investigation include: Anastrozole (ARIMIDEX™) (DRUG).
Who is sponsoring clinical trial NCT00241436?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00241436 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.